Marksans Pharma Ltd. has announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2024, reflecting strong growth in both revenue and profit.
Q2 FY25 Financial Highlights (Figures in Crores)
Quarter-over-Quarter (QoQ) Comparison:
- Revenue from Operations: ₹641.92 crore in Q2 FY25, up from ₹590.62 crore in Q1 FY25, marking a growth of 8.69%.
- Net Profit: ₹97.76 crore in Q2 FY25, compared to ₹89.07 crore in Q1 FY25, an increase of 9.76%.
Year-over-Year (YoY) Comparison:
- Revenue from Operations: ₹641.92 crore in Q2 FY25, up from ₹531.24 crore in Q2 FY24, a substantial growth of 20.84%.
- Net Profit: ₹97.76 crore in Q2 FY25, up from ₹83.87 crore in Q2 FY24, an increase of 16.56%.
This strong performance highlights Marksans Pharma’s solid market position and growth trajectory over the past year, with both quarterly and annual improvements in revenue and profit.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. The author or Business Upturn is not liable for any losses arising from the use of this information.
As of 1:08 pm the shares were trading 2.44% higher at ₹295.65 on NSE.
